Skip to main content
SpringerLink
Log in

Recommendations for the Health Economics Analysis to be Performed with a Drug to be Registered in Prevention or Treatment of Osteoporosis

  • Editorial
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

An Erratum to this article was published on 05 July 2013

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Evans D, Freund D, Dittus R, et al. (1990) The use of economic analysis as a basis for inclusion of pharmaceutical products on the Pharmaceutical Benefits Scheme. Department of Health Housing and Community Services, Commonwealth of Australia, Canberra

    Google Scholar 

  2. Ontario Guidelines for Economic Analysis of Pharmaceutical Products (1994) Ontario Ministry of Health

  3. Garattini L, Grilli R, Scopelliti D, Mantovani L (1995) A proposal for Italian guidelines in pharmacoeconomics. PharmacoEconomics 7:1–6

    Article  PubMed  CAS  Google Scholar 

  4. Task Force on Principles for Economic Analysis of Health Care Technology (1995) Economic analysis of health care technology. Ann Intern Med 122:61–70

    Google Scholar 

  5. Belgian Society for Pharmacoepidemiology. A proposal for methodological guidelines for economic evaluation of pharmaceuticals, Belgium

  6. Rovira J, Antonanzas F (1995) Economic analysis of health technologies and programmes: a Spanish proposal for methodological standardisation. PharmacoEconomics 8:245–252

    Article  PubMed  CAS  Google Scholar 

  7. Riggs BL, Melton LJ (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17:505S–515S

    Article  PubMed  CAS  Google Scholar 

  8. Zethraeus N, Stromberg L, Jonsson B, Svensson O, Ohlen G (1997) The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand 68[1]:13–17

    PubMed  CAS  Google Scholar 

  9. WHO Study Group on Assessment of Fracture Risk and its application to screening for postmenopausal osteoporosis (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. WHO, Geneva, (WHO technical series 843)

    Google Scholar 

  10. Medical Research Council Working Party (1985) MRC trial of treatment of mild hypertension: principal results. BMJ 291:97–104

    Article  Google Scholar 

  11. Shepherd J, Cobbe SM, Ford I, et al. (1995) Prevention of coronary artery disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301–1307

    Article  PubMed  CAS  Google Scholar 

  12. Johnston CC, Melton LJ (1995) Bone densitometry. In: Riggs BL, Melton LJ (eds) Osteoporosis: etiology, diagnosis, and management, 2nd ed. Lippincott-Raven, Philadelphia, pp 275–298

    Google Scholar 

  13. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259

    Article  PubMed  CAS  Google Scholar 

  14. Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. Bone Miner Res 9:(8)1137–1141

    Article  CAS  Google Scholar 

  15. Cummings SR (19 ) Treatable and untreatable risk factors for hip fractures. Bone 18:165S–167S

    Article  Google Scholar 

  16. US Preventive Services Task Force (1996) Screening for postmenopausal osteoporosis. In: Guide to clinical preventive services, 2nd ed.

    Google Scholar 

  17. US Congress, Office of Technology Assessment (1995) Hip fractures and outcomes in people age 50 and over. US Government Printing Office, Washington, DC

    Google Scholar 

  18. Hoffenberg R, James OF, Brocklehurst JC et al. (1989) Fractured neck of femur: prevention and management. Summary and recommendations of a report of the Royal College of Physicians. J R Coll Phys Lond 23:8–12

    Google Scholar 

  19. Levy E (1989) Cost analysis of osteoporosis related to untreated menopause. Clin Rheumatol 8(suppl 2):76–82

    Article  PubMed  Google Scholar 

  20. Lord SR, Sinnett PF (1986) Femoral neck fractures: admissions, bed use, outcome and projections. Med J Aust 145:493–496

    PubMed  CAS  Google Scholar 

  21. Gold DT (1995) The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 18(3):185S–189S

    Article  Google Scholar 

  22. Gold DT, Drezner MK (1995) In: Riggs BL, Melton LJ (eds) Quality of life in osteoporosis: etiology, diagnosis, and management, 2nd ed. Lippincott-Raven, Philadelphia, pp 475–486

  23. US Congress, Office of Technology Assessment (1995) Effectiveness and costs of osteoporosis screening and hormone replacement therapy, vol. 2: evidence on benefits, risks, and costs, OTA-BP-H-144. US Government Printing Office, Washington, DC

    Google Scholar 

  24. Jonsson B, Christiansen C, Johnell O, Hedbrandt J (1995) Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporosis Int 5:136–142

    Article  CAS  Google Scholar 

  25. Tosteson A, Weinstein MC (1991) Cost-effectiveness of hormone replacement therapy after the menopause. Bailliere’s Clin Obstet Gynaecol 5:00–00

    CAS  Google Scholar 

  26. Cauley JA, Seeley DG, Ensrud K, et al. (1995) Estrogen replacement therapy and fractures in older women. Ann Intern Med 122:9–16

    Article  PubMed  CAS  Google Scholar 

  27. Naessen T, Persson I, Adami HO, et al. (1990) Hormone replacement therapy and the risk for first hip fracture. Ann Intern Med 113:95–103

    Article  PubMed  CAS  Google Scholar 

  28. Chapuy MC, Arlot ME, Duboeuf F, et al. (1992) Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327:1637–1642

    Article  PubMed  CAS  Google Scholar 

  29. US Congress, Office of Technology Assessment (1995) Effectiveness and costs of osteoporosis screening and hormone replacement therapy, vol. 1: cost-effectiveness analysis, OTABP-H-160 US Government Printing Office, Washington, DC

    Google Scholar 

  30. Gafni A, Birch S (1993) Searching for a common currency: critical appraisal of the scientific basis underlying European harmonization of the measurement of Health-Related Quality of Life (EuroQoL). Health Policy 23:219–228

    Article  PubMed  CAS  Google Scholar 

  31. Coyle D, Tolley K (1992) Discounting of health benefits in the Pharmacoeconomic Analysis of drug therapies. An issue for debate? Pharmacoeconomics 2(2):153–162

    Article  PubMed  CAS  Google Scholar 

  32. Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137–145

    Article  PubMed  CAS  Google Scholar 

  33. Bakker C, Boers M, van der Linden SJ (1993) Measures to assess ankylosing spondylitis: taxonomy, review and recommendations. J Rheumatol 20:1724–1730

    PubMed  CAS  Google Scholar 

  34. Cook DJ, Guyatt GH, Adachi JD, Clifton J, Griffith LE, Epstein RS, Juniper EF (1993) Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum 36(6):750–756

    Article  PubMed  CAS  Google Scholar 

  35. Kanis JA, Minne WH, Meunier PJ, Ziegler R, Allender E (1992) Quality of life and vertebral osteoporosis. Osteoporosis Int 2:161–163

    Article  CAS  Google Scholar 

  36. Lips P, Agnusdei D, Caulin F, Cooper C, Johnell O, Kanis J, Liberman U, Minne H, Reeve J, Reginster JY, de Vernejoul MC, Wiklund I (1996) The development of a European questionnaire for quality of life in patients with vertebral osteoporosis. Scan J Rheumatol 25(S103):84–85

    Article  Google Scholar 

  37. Lips P, Cooper C, Agnusdei D, Caulin F, Egger P, Johnell O, Kanis J, Liberman U, Minne H, Reeve J, Reginster JY, Vernejoul MC, Wiklund I (1997) Quality of life as outcome in the treatment of osteoporosis: the development of a questionnaire for quality of life by the European Foundation for Osteoporosis. Osteoporosis Int 7:36–38

    Article  CAS  Google Scholar 

  38. Guillemin F, Bombardier C, Beaton D (1993) Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 46:1417–1432

    Article  PubMed  CAS  Google Scholar 

  39. Keene S, Parker MJ, Pryor GA (1993) Mortality and morbidity after hip fractures. BMJ 307:1248–1250

    Article  PubMed  CAS  Google Scholar 

  40. Magaziner J, Simonsick EM, Kashner T, Hebel JR (1988) Patient-proxy response comparability on measures of patient health and functional status. J Clin Epidemiol 41(11):1065–1074

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabetes Care & Endocrinology, Lilly Research Laboratories, Eli Lilly & Company, Lilly Corporate Centre, Indianapolis, IN, 46285, USA

    Dere W.

  2. Hospital Henri Mondor, 94010, Creteil, France

    B. Avouac

  3. Department of Internal Medicine/Rheumatology, University of Maastricht, Nederlands

    M. Boers

  4. Health Economics Research Group, Brunel, The University of West London, Uxbirdge, Middlesex, UB8 3PH, UK

    M. Buxton

  5. Center for Clinical & Basic Research, Ballerup Byvej 222, Ballerup, 2750, Denmark

    C. Christiansen & H. Lawetz

  6. Eli Lilly & Company Ltd., Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK

    A. Dawson

  7. Ospedale Santa Maria della Scale, 53100, Sienna, Italy

    C. Gennari

  8. Faculty of Medicine, School of Public Health, Nancy, France

    F. Guillemin

  9. Merck & Co., Inc., P.O. Box 4, West Point, PA, 19486-0004, USA

    F. Ornskov

  10. Proctor and Gamble Pharmaceuticals, Lovett House, Lovett Road, Staines, Middlesex, TW18 3AZ, UK

    I. Roumagnac

  11. Policliniques L. Brull, Service de Metabolisme Osseux, 45 Quai Godefroid Kurth, 4020, Liege, Belgium

    J. Y. Reginster

Authors
  1. Dere W.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Avouac
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Boers
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Buxton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Christiansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Dawson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Gennari
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. Guillemin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H. Lawetz
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F. Ornskov
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. I. Roumagnac
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J. Y. Reginster
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The authors represent the Group for the Respect of Ethics and Excellence in Science

An erratum to this article is available at http://dx.doi.org/10.1007/s00223-013-9760-4.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dere, W., Avouac, B., Boers, M. et al. Recommendations for the Health Economics Analysis to be Performed with a Drug to be Registered in Prevention or Treatment of Osteoporosis. Calcif Tissue Int 63, 93–97 (1998). https://doi.org/10.1007/BF03322783

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03322783

Search

Navigation